Zentalis Pharmaceuticals (NASDAQ:ZNTL) PT Lowered to $67.00

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Rating) had its target price dropped by equities research analysts at Guggenheim from $92.00 to $67.00 in a research note issued to investors on Wednesday, The Fly reports. Guggenheim’s price objective indicates a potential upside of 153.02% from the stock’s current price.

Several other brokerages also recently issued reports on ZNTL. Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, April 6th. They issued an “overweight” rating and a $67.00 target price for the company. Stifel Nicolaus cut their target price on shares of Zentalis Pharmaceuticals from $94.00 to $74.00 in a research note on Monday. Wedbush reiterated an “outperform” rating on shares of Zentalis Pharmaceuticals in a research note on Friday, February 25th. SVB Leerink cut their target price on shares of Zentalis Pharmaceuticals from $78.00 to $67.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Oppenheimer cut their target price on shares of Zentalis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $82.50.

Shares of NASDAQ ZNTL opened at $26.48 on Wednesday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -7.01 and a beta of 2.28. The business has a 50-day moving average of $46.56 and a 200-day moving average of $63.63. Zentalis Pharmaceuticals has a fifty-two week low of $25.17 and a fifty-two week high of $87.19.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Rating) last announced its quarterly earnings data on Thursday, February 24th. The company reported ($1.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.33) by $0.22. During the same period in the prior year, the firm posted ($1.01) earnings per share. On average, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -5.03 earnings per share for the current fiscal year.

In other news, SVP Dimitris Voliotis sold 601 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Monday, February 14th. The shares were sold at an average price of $50.23, for a total value of $30,188.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cam Gallagher sold 10,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Tuesday, January 18th. The shares were sold at an average price of $62.64, for a total transaction of $626,400.00. The disclosure for this sale can be found here. Insiders have sold 173,307 shares of company stock valued at $8,759,951 over the last 90 days. Company insiders own 21.00% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZNTL. Morgan Stanley raised its position in shares of Zentalis Pharmaceuticals by 29.0% in the second quarter. Morgan Stanley now owns 68,482 shares of the company’s stock valued at $3,643,000 after buying an additional 15,413 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in Zentalis Pharmaceuticals by 54.6% in the second quarter. Parametric Portfolio Associates LLC now owns 13,938 shares of the company’s stock valued at $742,000 after acquiring an additional 4,923 shares during the last quarter. Strs Ohio increased its stake in Zentalis Pharmaceuticals by 39.5% in the third quarter. Strs Ohio now owns 5,300 shares of the company’s stock valued at $353,000 after acquiring an additional 1,500 shares during the last quarter. SG Americas Securities LLC increased its stake in Zentalis Pharmaceuticals by 64.6% in the third quarter. SG Americas Securities LLC now owns 18,711 shares of the company’s stock valued at $1,247,000 after acquiring an additional 7,346 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in Zentalis Pharmaceuticals by 22.2% in the third quarter. Victory Capital Management Inc. now owns 4,934 shares of the company’s stock valued at $329,000 after acquiring an additional 898 shares during the last quarter. Institutional investors own 94.61% of the company’s stock.

About Zentalis Pharmaceuticals (Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

Further Reading

The Fly logo

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.